相关实验视频
Updated: Sep 17, 2025

06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
22.7K
氨酸丰富的重复激酶2:通往帕金森病的途径
Suzanne R Pfeffer1,2,3, Dario R Alessi2,3,4
1Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305-5307, USA pfeffer@stanford.edu.
Cold Spring Harbor perspectives in medicine
|June 30, 2025
概括
氨酸丰富的重复激酶2 (LRRK2) 突变通过改变Rab蛋白酸化来驱动帕金森病. LRRK2抑制剂通过逆转下游效应,如受损的鱼信号传输,显示出治疗潜力.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 神经科学是一个神经科学.
背景情况:
- 氨酸丰富的重复激酶2 (LRRK2) 突变是帕金森病 (PD) 的重要遗传因素.
- 了解LRRK2的激酶活性和下游效应对于PD病原和治疗开发至关重要.
研究的目的:
- 阐明LRRK2突变导致帕金森病的分子机制.
- 研究LRRK2在酸化Rab GTPases中的作用及其对细胞信号通路的影响.
- 评估LRRK2抑制剂在逆转PD相关细胞功能障碍方面的治疗潜力.
主要方法:
- 低温电子显微镜测定LRRK2结构和抑制剂结合.
- 生物化学试验研究LRRK2膜招募和Rab基底酸化.
- 细胞测试,以评估LRRK2激活对初级毛和刺信号传递的影响.
主要成果:
- LRRK2酸化特定的Rab GTPases,改变它们的结合伙伴.
- 激活LRRK2,特别是在溶酶体应激过程中,导致形成-Rab-effector复合体.
- 这些复杂物会破坏初级毛,并损害子信号传输,而LRRK2抑制剂可以逆转这些效应.
结论:
- 以LRRK2为媒介的鱼信号的破坏提供了遗传性和异常性帕金森病之间的联系.
- LRRK2抑制剂通过恢复正常的细胞功能来证明对帕金森病的治疗有希望.
相关概念视频
Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
MAPK Signaling Cascades
6.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.2K
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K

